Royal Bank Of Canada reissued their sector perform rating on shares of Amedisys Inc (NASDAQ:AMED) in a research report released on Thursday, MarketBeat reports. Royal Bank Of Canada currently has a $62.00 price target on the health services provider’s stock, up from their previous price target of $56.00.

Several other research firms also recently weighed in on AMED. Mizuho downgraded Amedisys from a buy rating to a neutral rating and set a $50.00 price objective on the stock. in a report on Wednesday, July 26th. BidaskClub downgraded Amedisys from a strong-buy rating to a buy rating in a report on Wednesday, July 12th. Benchmark Co. reissued a hold rating on shares of Amedisys in a report on Thursday. Robert W. Baird reissued a hold rating and set a $50.00 price objective on shares of Amedisys in a report on Wednesday, October 4th. Finally, Oppenheimer Holdings, Inc. reaffirmed a buy rating and set a $60.00 target price on shares of Amedisys in a research report on Friday, September 15th. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $61.00.

Amedisys (NASDAQ AMED) traded down $0.14 during midday trading on Thursday, hitting $56.25. The company had a trading volume of 310,900 shares, compared to its average volume of 485,523. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.21 and a current ratio of 1.33. Amedisys has a 12 month low of $38.00 and a 12 month high of $65.91. The firm has a market cap of $1,908.96, a P/E ratio of 26.91, a price-to-earnings-growth ratio of 1.37 and a beta of 0.68.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Tuesday, November 7th. The health services provider reported $0.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.54 by $0.02. Amedisys had a return on equity of 14.68% and a net margin of 2.88%. The company had revenue of $380.20 million for the quarter, compared to the consensus estimate of $384.59 million. During the same quarter last year, the business posted $0.36 EPS. Amedisys’s revenue for the quarter was up 5.1% on a year-over-year basis. equities research analysts anticipate that Amedisys will post 2.22 EPS for the current year.

WARNING: This report was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.thecerbatgem.com/2017/11/12/amedisys-inc-amed-earns-sector-perform-rating-from-royal-bank-of-canada.html.

Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of Amedisys by 0.7% in the 2nd quarter. Vanguard Group Inc. now owns 2,386,046 shares of the health services provider’s stock worth $149,867,000 after acquiring an additional 16,368 shares in the last quarter. American Century Companies Inc. raised its position in shares of Amedisys by 41.4% in the 3rd quarter. American Century Companies Inc. now owns 1,671,680 shares of the health services provider’s stock worth $93,547,000 after acquiring an additional 489,220 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of Amedisys by 29.7% in the 3rd quarter. Wells Fargo & Company MN now owns 1,484,041 shares of the health services provider’s stock worth $83,048,000 after acquiring an additional 339,825 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Amedisys by 0.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,124,943 shares of the health services provider’s stock worth $70,658,000 after acquiring an additional 7,963 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of Amedisys by 10.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 846,575 shares of the health services provider’s stock worth $47,375,000 after acquiring an additional 82,247 shares in the last quarter. 96.36% of the stock is owned by institutional investors and hedge funds.

About Amedisys

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Stock Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related stocks with our FREE daily email newsletter.